Suzanne Ildstad, Director at Talaris Therapeutics, Inc. (TALS), sold 297,964 shares at $2.14 ($639K) on 2023-04-17, disclosed to the SEC on 2023-04-19.
Scheduled sale ($639k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.14 | 99,771 | $214K | 33.4% |
| 2 | $2.14 | 99,771 | $214K | 33.4% |
| 3 | $2.15 | 49,211 | $106K | 16.6% |
| 4 | $2.15 | 49,211 | $106K | 16.6% |
| Total | $2.14 avg | 297,964 | $639K | 100% |
| Filing → |
| TALS | SELL | 2023-06-07 | $149K | — | Filing → |
| TALS | SELL | 2023-06-05 | $80K | — | Filing → |
| TALS | SELL | 2023-04-25 | $35K | — | Filing → |